Related Experiment Video

Updated: Nov 12, 2025

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

14.2K

Prevalence of G6PD deficiency in Iranian neonates with jaundice: a systematic review and meta-analysis

Maryam Javadi1,2, Somayeh Deravi2, Shabnam Zarei2

  • 1Children Growth Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
|March 16, 2021
PubMed

Insights

The overall prevalence of Glucose-6-phosphate dehydrogenase (G6PD) deficiency in Iranian neonates with jaundice is 7%. This G6PD deficiency is more common in males and necessitates screening to prevent complications.

Area of Science:

  • Medical Research
  • Neonatal Health
  • Genetic Disorders

Background:

  • Neonatal jaundice is a common condition, and Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a significant underlying cause.
  • Estimating the prevalence of G6PD deficiency in neonates with jaundice in Iran is crucial for public health planning and intervention.

Approach:

  • A systematic review and meta-analysis was conducted, searching major scientific databases up to December 2019.
  • Prevalence and 95% Confidence Intervals (CI) were calculated as summary measures.
  • Subgroup, meta-regression, and sensitivity analyses were performed to explore variations and robustness of the findings.

Key Points:

  • The pooled prevalence of G6PD deficiency among neonates with jaundice in Iran was found to be 7.0% (95% CI: 5.5-8.5%).
  • Prevalence was significantly higher in male neonates (12.1%) compared to female neonates (3.00%).
  • Sensitivity analyses confirmed the robustness of the pooled prevalence estimates.

Conclusions:

  • The study confirms a 7% prevalence of G6PD deficiency in Iranian neonates presenting with jaundice.
  • Higher prevalence in males and early hours of life suggests specific risk groups.
  • Routine screening for G6PD deficiency in neonates is recommended to mitigate potential complications.
Abstract

Keywords:
Glucosephosphate dehydrogenasedeficiencyjaundicemeta-analysisneonatal

More Related Videos

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.1K
Quantification of Colonic Stem Cell Mutations07:53

Quantification of Colonic Stem Cell Mutations

Published on: September 25, 2015

6.9K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
83
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
57
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
500
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
90
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
74
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.6K